Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **multi-component procedural injection kit** containing povidone-iodine, triamcinolone acetonide, lidocaine hydrochloride, and bupivacaine hydrochloride, typically packaged for office-based pain and anesthetic procedures such as joint injections, trigger point injections, and nerve blocks. Its pharmacology combines **skin antisepsis** from povidone-iodine, **anti-inflammatory glucocorticoid activity** from triamcinolone acetonide via glucocorticoid receptor signaling, and **local anesthetic/analgesic effects** from lidocaine and bupivacaine through blockade of voltage-gated sodium channels in peripheral nerves, thereby reducing nerve impulse conduction. Publicly described versions appear as compounded or specialty-distributed kits rather than a single branded innovator drug, and the available context indicates that these kits have appeared on DailyMed with labeling stating that they have **not been found by the FDA to be safe and effective** and that the labeling has **not been approved by the FDA**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on povidone-iodine + triamcinolone acetonide + lidocaine hydrochloride + bupivacaine hydrochloride.